FERMENTA.NS
HoldFallen FavouriteFermenta Biotech Limited · Healthcare · India · $143M cap · $1.8M/day traded
INR 486.50 -2.5% · close 15 Oct · scored 17 Oct
Fallen Favourite: A good business, still expensive, and the price is falling.
As of 17 Oct 2026, MoatMap's StockRank for Fermenta Biotech Limited (FERMENTA.NS) is 48/100, ranked against 24,000+ stocks in 35 markets (Quality 75, Value 44, Momentum 22, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT FERMENTA BIOTECH LIMITED
Read
Fermenta Biotech Limited, together with its subsidiaries, engages in the manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products in India, Europe, the United States, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3.5B | 3.3B | 4.7B | 5.2B | 14.5% | 5.1B |
| EPS (INR) | -17.70 | -7.99 | 26.35 | 24.70 | -6.3% | 20.74 |
| Shares | 28.9M | 28.9M | 29.2M | 28.7M | -0.6% | 28.7M |
| Debt | 2.2B | 1.4B | 1.1B | 1.1B | -19.8% | 1.1B |
| Equity | 3.2B | 2.9B | 3.6B | 4.1B | 8.8% | — |
| Op CF | 1.2B | 1.1B | 409.0M | 928.3M | -7.2% | 918.8M |
| Inv CF | -554.1M | -155.0M | -1.6M | -430.0M | — | — |
| Fin CF | -413.8M | -908.5M | -508.7M | -422.9M | — | — |
Not enough steady price history for a read yet.
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FERMENTA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FERMENTA.NS | Fermenta Biotech Limited(you) | $143M | 48 | Hold |
| SIGACHI.NS | Sigachi Industries Limited | $121M | 41 | Hold |
| AMRUTANJAN.NS | Amrutanjan Health Care Limited | $154M | 58 | Hold |
| THEMISMED.NS | Themis Medicare Limited | $114M | 57 | Hold |
| WANBURY.NS | Wanbury Limited | $82M | 54 | Hold |
| BAFNAPH.NS | Bafna Pharmaceuticals Limited | $85M | 55 | Hold |
| BAJAJHCARE.NS | Bajaj HealthCare Limited | $123M | 63 | Hold |
| KILITCH.NS | Kilitch Drugs (India) Limited | $79M | 58 | Hold |
| SHUKRAPHAR.NS | Shukra Pharmaceuticals Limited | $256M | 37 | Hold |
| ZIMLAB.NS | ZIM Laboratories Limited | $77M | 59 | Hold |
Peer medians: ROE 11.7% · P/E 40.7x · Gross margin 59.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.